<DOC>
	<DOCNO>NCT02678923</DOCNO>
	<brief_summary>This study proof concept , placebo-controlled , double-blind , randomize trial participant recent acute coronary syndrome ( ACS ) evaluate efficacy , pharmacokinetics , safety , tolerability , disease progression measure IVUS , pharmacodynamics MDCO-216 infusion . Eligible participant randomize receive 5 infusion MDCO-216 20 milligrams/kilogram ( mg/kg ) placebo 1:1 ratio .</brief_summary>
	<brief_title>MDCO-216 Infusions Leading Changes Atherosclerosis : A Novel Therapy Development Improve Cardiovascular Outcomes - Proof Concept Intravascular Ultrasound ( IVUS ) , Lipids , Other Surrogate Biomarkers Trial</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Have experience recent ACS event within 14 day screen require clinically indicated coronary angiogram . A qualify ACS event define follow : diagnosis qualify myocardial infarction ( MI ) event define abnormal level cardiac biomarkers ( troponin I T creatine kinase myoglobin [ CKMB ] mass ) least one determination great 99th percentile upper limit normal ( ULN ) laboratory least one following : chest discomfort symptom myocardial ischemia ( ≥10 minute ) rest within 24 hour prior hospitalization MI and/or new electrocardiogram ( ECG ) finding ( presumed new prior ECG available ) indicative acute myocardial ischemia absence leave ventricular hypertrophy leave bundle branch block ( LBB ) . Baseline coronary angiogram must meet follow criterion IVUS interrogation target artery : Target artery must accessible IVUS catheter Target artery must stenotic area ≥20 % &lt; 50 % lumen diameter angiographic visual estimation within length native coronary artery ( `` target segment '' ) image IVUS Target artery undergone prior percutaneous coronary intervention ( PCI ) coronary artery bypass graft surgery ( CABG ) Target artery currently candidate intervention likely candidate intervention treatment phase study second IVUS interrogation Day 36 ; target artery may bypass graft Target artery may culprit vessel previous MI . The target artery may follow : A lesion 60 % stenosis , distal target segment , provide area target PCI CABG A single branch `` target vessel '' may narrow ≤ 70 % visual estimation , provide branch question target PCI CABG . Willing able give inform consent initiation studyrelated procedure willing comply require study procedure . Baseline IVUS complete due nonqualifying coronary angiogram demonstrate : great 50 % reduction lumen leave main coronary artery visual estimation , extensive CAD target vessel IVUS interrogation . Baseline IVUS interrogation determine unacceptable Atherosclerosis Imaging Core Laboratory . STsegment elevation myocardial infarction ( STEMI ) within last 90 day Clinically significant heart disease , opinion Investigator , likely require CABG , PCI cardiac transplantation , surgical percutaneous valve repair , and/or replacement follow index IVUS imaging ( apply PCI occur result initial screening angiogram complete prior index IVUS imaging ) . New York Heart Failure Association Class III IV heart failure last known leave ventricular ejection fraction &lt; 30 % . Coronary artery bypass surgery &lt; 6 week prior qualify IVUS . Cardiac arrhythmia within 3 month prior randomization control medication . Uncontrolled severe hypertension : systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 millimeter mercury ( mmHg ) prior randomization despite antihypertensive therapy . Poorly control diabetes mellitus hemoglobin A1c ( HbA1c ) &gt; 10.0 % prior randomization . Active liver disease define know current infectious , neoplastic , metabolic pathology liver alanine aminotransferase , aspartate aminotransferase elevation &gt; 2 x ULN total bilirubin elevation &gt; 1.5 x ULN screen confirm repeat measurement least one week apart . Fasting triglyceride value &gt; 400 milligrams/deciliter ( mg/dL ) . Impaired kidney function define calculated glomerular filtration rate &lt; 60 milliliters/minute estimate glomerular filtration rate . In addition , participant 0.3 mg/dL 25 % increase serum creatinine initial 3 5 day follow angiography exclude study . Serious comorbid disease life expectancy participant short duration trial ( , acute systemic infection , cancer , serious illness ) . This include cancer exception treat basalcell carcinoma occur &gt; 3 year screen . Body weight &gt; 120 kilogram ( kg ) . Females pregnant nursing , childbearing potential unwilling use least 2 method contraception ( oral contraceptive , barrier method , approve contraceptive implant , long term injectable contraception , intrauterine device tubal litigation ) . Women &gt; 2 year postmenopausal define ≥1 year since last menstrual period &gt; 55 year old negative pregnancy test within 24 hour randomization surgically sterile exempt exclusion . Males unwilling use acceptable method birth control entire study period ( , condom spermicide ) . Previous participation study precede study ETC216 , MDCO216 , similar investigational medicine contain apolipoprotein AI ( ApoAI ) proteins . Known allergy phospholipid component investigational product ( dimeric recombinant ApoAIM , 1Palmitoyl2oleoylsnglycero3phosphocholine , mannitol sucrose phosphate buffer ) . Treatment investigational medicinal product device within 30 day 5half˗lives , whichever longer . Known history alcohol and/or drug abuse . Use investigational medicinal product device course study , exclude PostMarketing Registries . Any condition accord investigator could interfere conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>